{"id":917501,"date":"2025-12-08T16:05:04","date_gmt":"2025-12-08T21:05:04","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholders-who-lost-money-in-shares-of-telix-pharmaceuticals-ltd-nasdaq-tlx-should-contact-wolf-haldenstein-immediately-6\/"},"modified":"2025-12-08T16:05:04","modified_gmt":"2025-12-08T21:05:04","slug":"shareholders-who-lost-money-in-shares-of-telix-pharmaceuticals-ltd-nasdaq-tlx-should-contact-wolf-haldenstein-immediately-6","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholders-who-lost-money-in-shares-of-telix-pharmaceuticals-ltd-nasdaq-tlx-should-contact-wolf-haldenstein-immediately-6\/","title":{"rendered":"Shareholders who lost money in shares of Telix Pharmaceuticals Ltd. (NASDAQ: TLX) Should Contact Wolf Haldenstein Immediately"},"content":{"rendered":"<div class=\"xn-newslines\">\n<p class=\"xn-distributor\">PR Newswire<\/p>\n<\/p><\/div>\n<div class=\"xn-content\">\n<p class=\"prntac\">\n        <b>Lead Plaintiff Deadline is <span class=\"xn-chron\">January 9, 2026<\/span><\/b>\n      <\/p>\n<p>\n        <span class=\"legendSpanClass\"><br \/>\n          <span class=\"xn-location\">NEW YORK<\/span><br \/>\n        <\/span>, <span class=\"legendSpanClass\"><span class=\"xn-chron\">Dec. 8, 2025<\/span><\/span> \/PRNewswire\/ &#8212;\u00a0<a href=\"https:\/\/edge.prnewswire.com\/c\/link\/?t=0&amp;l=en&amp;o=4574854-4&amp;h=2450732455&amp;u=https%3A%2F%2Fwww.whafh.com%2Fcase%2Ftelix-pharmaceuticals-ltd-nasdaq-tlx%2F&amp;a=Wolf+Haldenstein+Adler+Freeman+%26+Herz+LLP\" target=\"_blank\" rel=\"nofollow\"><span class=\"xn-person\">Wolf Haldenstein Adler Freeman<\/span> &amp; Herz LLP<\/a>\u00a0reminds purchasers or acquirers of <b>Telix Pharmaceuticals Ltd. (NASDAQ: TLX)<\/b>\u00a0<b>(&#8220;Telix&#8221;) <\/b>American Depositary Shares (&#8220;ADS&#8221;) that a securities class action has been filed. The class period is between <b><span class=\"xn-chron\">February 21, 2025<\/span> and <span class=\"xn-chron\">August 28, 2025<\/span><\/b>, inclusive. Investors have until <b><span class=\"xn-chron\">January 9<\/span>, 2026\u00a0<\/b>to seek appointment as <b>lead plaintiff.<\/b>\u00a0<\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder1\">\n<p>\n          <a href=\"https:\/\/mma.prnewswire.com\/media\/1064977\/Wolf_Haldenstein_Adler_Freeman_Logo.html\" target=\"_blank\" rel=\"nofollow\"><br \/>\n            <img decoding=\"async\" src=\"https:\/\/mma.prnewswire.com\/media\/1064977\/Wolf_Haldenstein_Adler_Freeman_Logo.jpg\" title=\"(PRNewsfoto\/Wolf Haldenstein Adler Freeman )\" alt=\"(PRNewsfoto\/Wolf Haldenstein Adler Freeman )\" \/><br \/>\n          <\/a>\n        <\/p>\n<\/p><\/div>\n<p class=\"prntac\">\n        <b><br \/>\n          <a href=\"https:\/\/edge.prnewswire.com\/c\/link\/?t=0&amp;l=en&amp;o=4574854-4&amp;h=485599886&amp;u=https%3A%2F%2Fwww.whafh.com%2Fcase%2Ftelix-pharmaceuticals-ltd-nasdaq-tlx%2F&amp;a=PLEASE+CLICK+HERE+TO+JOIN+THE+CASE+AND+SUBMIT+CONTACT+INFORMATION\" target=\"_blank\" rel=\"nofollow\">PLEASE CLICK HERE TO JOIN THE CASE AND SUBMIT CONTACT INFORMATION<\/a><br \/>\n        <\/b>\n      <\/p>\n<p>\n        <b>Allegations:<\/b>\n      <\/p>\n<p>The lawsuit\u00a0<span>alleges<\/span> violations of the Securities Exchange Act of 1934, claiming that Telix and its executives:<\/p>\n<ol type=\"1\">\n<li>\n          <b>Overstated progress<\/b> on the company&#8217;s prostate cancer therapeutic candidates.<\/li>\n<li>\n          <b>Overstated the quality<\/b> of its supply chain and partner operations.<\/li>\n<\/ol>\n<p>\n        <b>Key Events:<\/b>\n      <\/p>\n<ul type=\"disc\">\n<li>On <span class=\"xn-chron\">February 20, 2025<\/span>, after market close, Telix held its earnings call for the 2024 fiscal year (the &#8220;2024 Call&#8221;). In the call, defendants represented that they were <i>&#8220;making great progress across our therapeutic pipeline, notably in the late-stage assets being brain, kidney and, of course, our prostate cancer program which is now in Phase 3. And we have had some really exciting developments across the next generation pipeline including delivery of a clinical proof-of-concept for our prostate cancer alpha candidate. It has been a year of many acquisitions, and these are supporting the strategic expansion of our pipeline and the build out of our global product delivery or manufacturing infrastructure. So in short, the business looks very different to what it did a year ago and at the end of 2025 it will look very different again as a result of this great progress.&#8221;\n<p><\/i><\/li>\n<li>On <span class=\"xn-chron\">July 22, 2025<\/span>, before the market opened, Telix filed with the United States Securities and Exchange Commission (&#8220;SEC&#8221;) a current report on Form 6-K reporting that the SEC had issued a subpoena for documents and information relating to the Company&#8217;s development of its prostate cancer therapeutic candidates. On <span class=\"xn-chron\">July 22, 2025<\/span>, after market close, Bloomberg published an article entitled &#8220;Telix Shares Drop as SEC Probes Disclosures Tied to Prostate Cancer Drug Pipeline.&#8221; This article stated that <i>&#8220;[Telix] slumped as much as 16%, the most in 21 months, after the Australian developer of radioactive drugs said it received a subpoena from the [SEC] seeking information about disclosures related to its prostate cancer therapeutic candidates.&#8221;<\/i> On this news, Telix ADSs fell <span class=\"xn-money\">$1.70<\/span> per ADS, or 10.4%, to close at <span class=\"xn-money\">$14.58<\/span> on <span class=\"xn-chron\">July 23, 2025<\/span>. The next day, Telix ADSs fell a further <span class=\"xn-money\">$0.69<\/span> per ADS, or 4.7%, to close at <span class=\"xn-money\">$13.89<\/span> on <span class=\"xn-chron\">July 24, 2025<\/span>.\n<\/li>\n<li>On <span class=\"xn-chron\">August 28, 2025<\/span>, Telix posted an announcement on its website that the FDA had issued a Complete Response Letter for its renal cancer drug candidate requesting additional data. On this news, the price of Telix ADSs fell <span class=\"xn-money\">$1.95<\/span> per ADS, or 16.1%, to close at <span class=\"xn-money\">$10.15<\/span> on <span class=\"xn-chron\">August 28, 2025<\/span>. The next day, Telix ADSs fell a further <span class=\"xn-money\">$0.60<\/span> per ADS, or 5.9%, to close at <span class=\"xn-money\">$9.55<\/span> on <span class=\"xn-chron\">August 29, 2025<\/span>.<\/li>\n<\/ul>\n<p class=\"prntac\">\n        <b>Why\u00a0<\/b><br \/>\n        <a href=\"https:\/\/edge.prnewswire.com\/c\/link\/?t=0&amp;l=en&amp;o=4574854-4&amp;h=1290291941&amp;u=https%3A%2F%2Fwww.whafh.com%2Fcase%2Ftelix-pharmaceuticals-ltd-nasdaq-tlx%2F&amp;a=Wolf+Haldenstein+Adler+Freeman+%26+Herz+LLP%3F\" target=\"_blank\" rel=\"nofollow\"><br \/>\n          <b><br \/>\n            <span class=\"xn-person\">Wolf Haldenstein Adler Freeman<\/span> &amp; Herz LLP?<\/b><br \/>\n        <\/a><br \/>\n        <b>:<\/b>\n      <\/p>\n<p>This illustrious <a href=\"https:\/\/edge.prnewswire.com\/c\/link\/?t=0&amp;l=en&amp;o=4574854-4&amp;h=3149247821&amp;u=https%3A%2F%2Fwww.whafh.com%2Fcase%2Ftelix-pharmaceuticals-ltd-nasdaq-tlx%2F&amp;a=firm\" target=\"_blank\" rel=\"nofollow\">firm<\/a>, founded in 1888, is steadfast in their pursuit of justice for investors who have suffered financial harm due to these misrepresented statements.\u00a0The <a href=\"https:\/\/edge.prnewswire.com\/c\/link\/?t=0&amp;l=en&amp;o=4574854-4&amp;h=125520652&amp;u=https%3A%2F%2Fwww.whafh.com%2Fcase%2Ftelix-pharmaceuticals-ltd-nasdaq-tlx%2F&amp;a=law+firm%C2%A0\" target=\"_blank\" rel=\"nofollow\">law firm\u00a0<\/a>brings to the fore over 125 years of legal expertise in securities litigation and has a proven track record of protecting the rights of investors.<\/p>\n<p>We encourage all investors who have been affected or have information that will assist in our investigation, to contact\u00a0<a href=\"https:\/\/edge.prnewswire.com\/c\/link\/?t=0&amp;l=en&amp;o=4574854-4&amp;h=2450732455&amp;u=https%3A%2F%2Fwww.whafh.com%2Fcase%2Ftelix-pharmaceuticals-ltd-nasdaq-tlx%2F&amp;a=Wolf+Haldenstein+Adler+Freeman+%26+Herz+LLP\" target=\"_blank\" rel=\"nofollow\"><span class=\"xn-person\">Wolf Haldenstein Adler Freeman<\/span> &amp; Herz LLP<\/a>.<\/p>\n<p>\n        <b>Contact:<\/b>\n      <\/p>\n<ul type=\"disc\">\n<li>\n          <b>Phone:<\/b>\u00a0(800) 575-0735 or (212) 545-4774<\/p>\n<\/li>\n<li>\n          <b>Email:\u00a0<\/b><br \/>\n          <a href=\"mailto:classmember@whafh.com\" target=\"_blank\" rel=\"nofollow\">classmember@whafh.com<\/a><\/p>\n<\/li>\n<li>\n          <b>Contact Person:<\/b>\u00a0<a href=\"mailto:gstone@whafh.com\" target=\"_blank\" rel=\"nofollow\"><span class=\"xn-person\">Gregory Stone<\/span>, Director of Case and Financial Analysis<\/a><\/li>\n<\/ul>\n<p>\n        <b>Firm Website:<\/b><br \/>\n        <a href=\"https:\/\/edge.prnewswire.com\/c\/link\/?t=0&amp;l=en&amp;o=4574854-4&amp;h=2822830844&amp;u=https%3A%2F%2Fwww.whafh.com%2Fcase%2Ftelix-pharmaceuticals-ltd-nasdaq-tlx%2F&amp;a=%C2%A0Wolf+Haldenstein+Adler+Freeman+%26+Herz+LLP\" target=\"_blank\" rel=\"nofollow\">\u00a0Wolf Haldenstein Adler Freeman &amp; Herz LLP<\/a>\n      <\/p>\n<p>This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.<\/p>\n<p id=\"PURL\">\n        <img loading=\"lazy\" decoding=\"async\" title=\"Cision\" width=\"12\" height=\"12\" alt=\"Cision\" src=\"https:\/\/edge.prnewswire.com\/c\/img\/favicon.png?sn=NY41659&amp;sd=2025-12-08\" \/> View original content to download multimedia:<a id=\"PRNURL\" rel=\"nofollow\" href=\"https:\/\/www.prnewswire.com\/news-releases\/shareholders-who-lost-money-in-shares-of-telix-pharmaceuticals-ltd-nasdaq-tlx-should-contact-wolf-haldenstein-immediately-302635748.html\" target=\"_blank\">https:\/\/www.prnewswire.com\/news-releases\/shareholders-who-lost-money-in-shares-of-telix-pharmaceuticals-ltd-nasdaq-tlx-should-contact-wolf-haldenstein-immediately-302635748.html<\/a><\/p>\n<p>SOURCE  <span class=\"xn-person\">Wolf Haldenstein Adler Freeman<\/span> &amp; Herz LLP<\/p>\n<\/p><\/div>\n<p>    <img decoding=\"async\" alt=\"\" src=\"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=NY41659&amp;Transmission_Id=202512081601PR_NEWS_USPR_____NY41659&amp;DateId=20251208\" style=\"border:0px;width:1px;height:1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>PR Newswire Lead Plaintiff Deadline is January 9, 2026 NEW YORK , Dec. 8, 2025 \/PRNewswire\/ &#8212;\u00a0Wolf Haldenstein Adler Freeman &amp; Herz LLP\u00a0reminds purchasers or acquirers of Telix Pharmaceuticals Ltd. (NASDAQ: TLX)\u00a0(&#8220;Telix&#8221;) American Depositary Shares (&#8220;ADS&#8221;) that a securities class action has been filed. The class period is between February 21, 2025 and August 28, 2025, inclusive. Investors have until January 9, 2026\u00a0to seek appointment as lead plaintiff.\u00a0 PLEASE CLICK HERE TO JOIN THE CASE AND SUBMIT CONTACT INFORMATION Allegations: The lawsuit\u00a0alleges violations of the Securities Exchange Act of 1934, claiming that Telix and its executives: Overstated progress on the company&#8217;s prostate cancer therapeutic candidates. Overstated the quality of its supply chain and partner operations. Key Events: On February 20, &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/shareholders-who-lost-money-in-shares-of-telix-pharmaceuticals-ltd-nasdaq-tlx-should-contact-wolf-haldenstein-immediately-6\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Shareholders who lost money in shares of Telix Pharmaceuticals Ltd. (NASDAQ: TLX) Should Contact Wolf Haldenstein Immediately&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-917501","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Shareholders who lost money in shares of Telix Pharmaceuticals Ltd. (NASDAQ: TLX) Should Contact Wolf Haldenstein Immediately - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/shareholders-who-lost-money-in-shares-of-telix-pharmaceuticals-ltd-nasdaq-tlx-should-contact-wolf-haldenstein-immediately-6\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Shareholders who lost money in shares of Telix Pharmaceuticals Ltd. (NASDAQ: TLX) Should Contact Wolf Haldenstein Immediately - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire Lead Plaintiff Deadline is January 9, 2026 NEW YORK , Dec. 8, 2025 \/PRNewswire\/ &#8212;\u00a0Wolf Haldenstein Adler Freeman &amp; Herz LLP\u00a0reminds purchasers or acquirers of Telix Pharmaceuticals Ltd. (NASDAQ: TLX)\u00a0(&#8220;Telix&#8221;) American Depositary Shares (&#8220;ADS&#8221;) that a securities class action has been filed. The class period is between February 21, 2025 and August 28, 2025, inclusive. Investors have until January 9, 2026\u00a0to seek appointment as lead plaintiff.\u00a0 PLEASE CLICK HERE TO JOIN THE CASE AND SUBMIT CONTACT INFORMATION Allegations: The lawsuit\u00a0alleges violations of the Securities Exchange Act of 1934, claiming that Telix and its executives: Overstated progress on the company&#8217;s prostate cancer therapeutic candidates. Overstated the quality of its supply chain and partner operations. Key Events: On February 20, &hellip; Continue reading &quot;Shareholders who lost money in shares of Telix Pharmaceuticals Ltd. (NASDAQ: TLX) Should Contact Wolf Haldenstein Immediately&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/shareholders-who-lost-money-in-shares-of-telix-pharmaceuticals-ltd-nasdaq-tlx-should-contact-wolf-haldenstein-immediately-6\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-12-08T21:05:04+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnewswire.com\/media\/1064977\/Wolf_Haldenstein_Adler_Freeman_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholders-who-lost-money-in-shares-of-telix-pharmaceuticals-ltd-nasdaq-tlx-should-contact-wolf-haldenstein-immediately-6\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholders-who-lost-money-in-shares-of-telix-pharmaceuticals-ltd-nasdaq-tlx-should-contact-wolf-haldenstein-immediately-6\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Shareholders who lost money in shares of Telix Pharmaceuticals Ltd. (NASDAQ: TLX) Should Contact Wolf Haldenstein Immediately\",\"datePublished\":\"2025-12-08T21:05:04+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholders-who-lost-money-in-shares-of-telix-pharmaceuticals-ltd-nasdaq-tlx-should-contact-wolf-haldenstein-immediately-6\\\/\"},\"wordCount\":616,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholders-who-lost-money-in-shares-of-telix-pharmaceuticals-ltd-nasdaq-tlx-should-contact-wolf-haldenstein-immediately-6\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1064977\\\/Wolf_Haldenstein_Adler_Freeman_Logo.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholders-who-lost-money-in-shares-of-telix-pharmaceuticals-ltd-nasdaq-tlx-should-contact-wolf-haldenstein-immediately-6\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholders-who-lost-money-in-shares-of-telix-pharmaceuticals-ltd-nasdaq-tlx-should-contact-wolf-haldenstein-immediately-6\\\/\",\"name\":\"Shareholders who lost money in shares of Telix Pharmaceuticals Ltd. (NASDAQ: TLX) Should Contact Wolf Haldenstein Immediately - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholders-who-lost-money-in-shares-of-telix-pharmaceuticals-ltd-nasdaq-tlx-should-contact-wolf-haldenstein-immediately-6\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholders-who-lost-money-in-shares-of-telix-pharmaceuticals-ltd-nasdaq-tlx-should-contact-wolf-haldenstein-immediately-6\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1064977\\\/Wolf_Haldenstein_Adler_Freeman_Logo.jpg\",\"datePublished\":\"2025-12-08T21:05:04+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholders-who-lost-money-in-shares-of-telix-pharmaceuticals-ltd-nasdaq-tlx-should-contact-wolf-haldenstein-immediately-6\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholders-who-lost-money-in-shares-of-telix-pharmaceuticals-ltd-nasdaq-tlx-should-contact-wolf-haldenstein-immediately-6\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholders-who-lost-money-in-shares-of-telix-pharmaceuticals-ltd-nasdaq-tlx-should-contact-wolf-haldenstein-immediately-6\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1064977\\\/Wolf_Haldenstein_Adler_Freeman_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1064977\\\/Wolf_Haldenstein_Adler_Freeman_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholders-who-lost-money-in-shares-of-telix-pharmaceuticals-ltd-nasdaq-tlx-should-contact-wolf-haldenstein-immediately-6\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Shareholders who lost money in shares of Telix Pharmaceuticals Ltd. (NASDAQ: TLX) Should Contact Wolf Haldenstein Immediately\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Shareholders who lost money in shares of Telix Pharmaceuticals Ltd. (NASDAQ: TLX) Should Contact Wolf Haldenstein Immediately - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholders-who-lost-money-in-shares-of-telix-pharmaceuticals-ltd-nasdaq-tlx-should-contact-wolf-haldenstein-immediately-6\/","og_locale":"en_US","og_type":"article","og_title":"Shareholders who lost money in shares of Telix Pharmaceuticals Ltd. (NASDAQ: TLX) Should Contact Wolf Haldenstein Immediately - Market Newsdesk","og_description":"PR Newswire Lead Plaintiff Deadline is January 9, 2026 NEW YORK , Dec. 8, 2025 \/PRNewswire\/ &#8212;\u00a0Wolf Haldenstein Adler Freeman &amp; Herz LLP\u00a0reminds purchasers or acquirers of Telix Pharmaceuticals Ltd. (NASDAQ: TLX)\u00a0(&#8220;Telix&#8221;) American Depositary Shares (&#8220;ADS&#8221;) that a securities class action has been filed. The class period is between February 21, 2025 and August 28, 2025, inclusive. Investors have until January 9, 2026\u00a0to seek appointment as lead plaintiff.\u00a0 PLEASE CLICK HERE TO JOIN THE CASE AND SUBMIT CONTACT INFORMATION Allegations: The lawsuit\u00a0alleges violations of the Securities Exchange Act of 1934, claiming that Telix and its executives: Overstated progress on the company&#8217;s prostate cancer therapeutic candidates. Overstated the quality of its supply chain and partner operations. Key Events: On February 20, &hellip; Continue reading \"Shareholders who lost money in shares of Telix Pharmaceuticals Ltd. (NASDAQ: TLX) Should Contact Wolf Haldenstein Immediately\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholders-who-lost-money-in-shares-of-telix-pharmaceuticals-ltd-nasdaq-tlx-should-contact-wolf-haldenstein-immediately-6\/","og_site_name":"Market Newsdesk","article_published_time":"2025-12-08T21:05:04+00:00","og_image":[{"url":"https:\/\/mma.prnewswire.com\/media\/1064977\/Wolf_Haldenstein_Adler_Freeman_Logo.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholders-who-lost-money-in-shares-of-telix-pharmaceuticals-ltd-nasdaq-tlx-should-contact-wolf-haldenstein-immediately-6\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholders-who-lost-money-in-shares-of-telix-pharmaceuticals-ltd-nasdaq-tlx-should-contact-wolf-haldenstein-immediately-6\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Shareholders who lost money in shares of Telix Pharmaceuticals Ltd. (NASDAQ: TLX) Should Contact Wolf Haldenstein Immediately","datePublished":"2025-12-08T21:05:04+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholders-who-lost-money-in-shares-of-telix-pharmaceuticals-ltd-nasdaq-tlx-should-contact-wolf-haldenstein-immediately-6\/"},"wordCount":616,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholders-who-lost-money-in-shares-of-telix-pharmaceuticals-ltd-nasdaq-tlx-should-contact-wolf-haldenstein-immediately-6\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/1064977\/Wolf_Haldenstein_Adler_Freeman_Logo.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholders-who-lost-money-in-shares-of-telix-pharmaceuticals-ltd-nasdaq-tlx-should-contact-wolf-haldenstein-immediately-6\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholders-who-lost-money-in-shares-of-telix-pharmaceuticals-ltd-nasdaq-tlx-should-contact-wolf-haldenstein-immediately-6\/","name":"Shareholders who lost money in shares of Telix Pharmaceuticals Ltd. (NASDAQ: TLX) Should Contact Wolf Haldenstein Immediately - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholders-who-lost-money-in-shares-of-telix-pharmaceuticals-ltd-nasdaq-tlx-should-contact-wolf-haldenstein-immediately-6\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholders-who-lost-money-in-shares-of-telix-pharmaceuticals-ltd-nasdaq-tlx-should-contact-wolf-haldenstein-immediately-6\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/1064977\/Wolf_Haldenstein_Adler_Freeman_Logo.jpg","datePublished":"2025-12-08T21:05:04+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholders-who-lost-money-in-shares-of-telix-pharmaceuticals-ltd-nasdaq-tlx-should-contact-wolf-haldenstein-immediately-6\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/shareholders-who-lost-money-in-shares-of-telix-pharmaceuticals-ltd-nasdaq-tlx-should-contact-wolf-haldenstein-immediately-6\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholders-who-lost-money-in-shares-of-telix-pharmaceuticals-ltd-nasdaq-tlx-should-contact-wolf-haldenstein-immediately-6\/#primaryimage","url":"https:\/\/mma.prnewswire.com\/media\/1064977\/Wolf_Haldenstein_Adler_Freeman_Logo.jpg","contentUrl":"https:\/\/mma.prnewswire.com\/media\/1064977\/Wolf_Haldenstein_Adler_Freeman_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholders-who-lost-money-in-shares-of-telix-pharmaceuticals-ltd-nasdaq-tlx-should-contact-wolf-haldenstein-immediately-6\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Shareholders who lost money in shares of Telix Pharmaceuticals Ltd. (NASDAQ: TLX) Should Contact Wolf Haldenstein Immediately"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/917501","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=917501"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/917501\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=917501"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=917501"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=917501"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}